CClinicalTrials.gg
CompletedNCT03254641Updated Nov 15, 2024

Calciotropic Effects After HCG Stimulation Test

An observational study in Hypogonadism, Male, sponsored by Martin Blomberg Jensen. Completed at 2 sites in Denmark. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by Martin Blomberg Jensen · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
242
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

We have in a pilot study found that serum calcium levels change in response to hCG stimulation test. We observed that serum calcium level measured at baseline and 72 hours after hCG stimulation were different in men with gonadal insufficiency referred for this stimulation test. Now we want to investigate a large cohort of men referred for hCG stimulation test due to suspected impaired gonadal function.

Read the detailed description

Introduction:

hCG signals through the LHCGR receptor and is know to stimulate testosterone production. hCG stimulation tests are therefore used to evaulate the capacity of the testis to respond to LH/hCG and thereby determine the degree og gonadal insufficiency and need for testosterone supplementation. Some groups have found LHCRG in extragondal tissues indicating a direct effect of hCG/LH outside the gonads. We noticed that some men with gonadal insuffciency had a low calcium level after hCG stimulation test. Now we would like to investigate whether this putative effect on calcium homeostasis of hCG is due to a direct effect or an indirect effect through testosterone or other sex steroids that also change in response to hCG stimulation. Moreover, we would like to clarify whether the chnage in calcium is compensated by classical regulators such as PTH, 1,25OH2D3, calcitonin, phosphate, CTX, alkaline phosphatase or other factors.

Aim of study:

The purpose of this study is to describe changes in calcium and calciotropic hormones after hCG stimulation test

DESIGN This is a prospective observational study

Patients and methods 100 men referred for hCG stimulation test due to suspected gonadal insuffciency age 18-60 years at Department of growth and reproduction, Rigshospitalet

Exclusion criteria are

intake of high dose calcium (above 1 mg daily) Known Disorders related to calcium metabolism, hypercalcemia, Granulomatous disease such as Wegener, tuberculosis, etc,

SAMPLE SIZE CALCULATION AND STATISTICS By using a test level of 5% (level of significance), power of 80% and at least 100 men completing the trial will enable us to detect a change in calcium of 10%, and a change in serum PTH of 30%.

SCREENING AND TIME COURSE Men referred for hCG stimulation test at ourDepartment will be screened for eligibility to the study. Those who meet the criteria for participation will be informed, and if they consent allocated to the study.

Each person will have one blood sampling performed prior to the test and 72 and 96 hours after the test.

Blood samples Venus blood is drawn preoperatively before hCG administration, 72 and 96 hours after. Serum will be send for analysis within 45 minutes and the rest frozen within 1 hour and will be stored at minus 20 degrees celsius until analysis.

OUTCOME MEASUREMENTS

Primary endpoints

•Changes in total, albumin corrected and ionized calcium

Main Secondary endpoints

  • Changes in PTH
  • Changes in 1,25OH2D3
  • Changes in Phosphate
  • Changes in FGF23
  • Changes in Calcitonin
  • Changes in LHCGR in serum
  • Changes in Cortisol
  • Changes in total and free testosterone
  • Changes in total and free estradiol
  • Changes in kidney function (GFR/creatinin)
  • Changes in gonadotropins
  • Changes in 25OHD, 24,25OH2D3
  • Changes in serum concentrations of putative regulators and downstream signals osteocalcin, osteopontin, RANKL, osteoprotegerin (OPG), alpha Klotho, Sclerostin and IGF-1.

Temporal changes in serum level of binding proteins. differences for vitamin D binding protein, albumin and sex hormone binding globulin.

Predefined subgroups orchiectomized men/ bilaterally irradiated testis High versus low baseline estradiol/testosterone Low/high calcium/PTH baseline

ANALYSIS AND INTERVENTION

Reproductive hormones and growth factors will be analysed at dept. of GR, Rigshospitalet. Other serum analyses will be analysed at Department of clinical biochemistry, and Aarhus Kommune Hospital

ETHICS AND SIDE EFFECTS All the patients will have full-filled their investigation, before they are invited to the study. They will be informed of potential adverse effects, and they can leave the trial at any point without any consequences. This study poses no additional risk to the patients except for the blood samples as everything else is according to standard clinical practice.

PUBLICATION OF RESULTS All results, positive or negative will be submitted to peer reviewed scientific journals. Data will successively be obtained and transferred to a statistical database.

02

Conditions studied

  • Hypogonadism, Male
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

men with suspected gonadal i suffciency ofter after orchiectomy or bilateral irradiation due to testis cancer

Inclusion criteria

  • men aged 18-60 years referred for hCG stimulation test due to previous treatment for testis cancer

Exclusion criteria

Exclusion Criteria:

  • high intake calcium
  • know disorders in calcium homeostasis
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
242 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • hypogondal men

    men referred for hCG stimulation test

    Drug: human chorionic gonadotropin

Interventions

  • Drughuman chorionic gonadotropin

    5000 IE times one

    Also known as: hCG

05

What researchers measure

Primary outcomes

  1. change in total, albumin corrected or ionized calcium

    mmol/l

    Time frame: 72 and 96 hours after hCG injection

Secondary outcomes

  1. PTH

    Time frame: 72 and 96 hours after hCG injection

  2. 1,25OH2D3

    Time frame: 72 and 96 hours after hCG injection

  3. Phosphate

    Time frame: 72 and 96 hours after hCG injection

  4. cortisol

    Time frame: 72 and 96 hours after hCG injection

  5. total and free testosterone

    Time frame: 72 and 96 hours after hCG injection

  6. total and free estradiol

    Time frame: 72 and 96 hours after hCG injection

  7. albumin, Shbg, VDBP

    Time frame: 72 and 96 hours after hCG injection

  8. 25OHD or 24,25OH2D3

    Time frame: 72 and 96 hours after hCG injection

  9. bone factors such as CTX, osteocalcin, RANKL, FGF23

    Time frame: 72 and 96 hours after hCG injection

  10. LHCGR

    in serum

    Time frame: 72 and 96 hours after hCG injection

  11. kidney function

    eGFR/creatinine

    Time frame: 72 and 96 hours after hCG injection

06

Study locations

2 sites
  • Department of Growth and Reproduction, Rigshospitalet
    Copenhagen, 2100, Denmark
  • Rigshospitalet
    Copenhagen, 2100, Denmark
07

References and documents

Individual participant data

Plan to share: Yes — share all available data through danish data archive

Supporting information: Study protocol

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03254641
Lead sponsor
Martin Blomberg Jensen
Responsible party
Martin Blomberg Jensen (MD, group leader, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Aug 18, 2017
Start date
Apr 1, 2017
Primary completion
Sep 30, 2020
Completion
Oct 6, 2021
Last update
Nov 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion